Nexalin Technology Inc (NXL) Stock Price, Quote & News

Company Profile

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injur...

Industry: Medical Devices

Sector: Healthcare

Phone: 832 260 0222

Website: www.nexalin.com

Address:

1776 Yorktown, Suite 550, Houston, United States

Azlvr Nov. 21 at 7:42 PM

$NXL 😬 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

Stockprofiler Nov. 18 at 5:43 PM

$ILLR #Undervalued (Nasdaq: ILLR) #BKFC is valued at over $400M and as much as $1B 2025-2026 •TRILLER currently seriously undervalued at $140M •News highly anticipated based on most recent PRs https://nasdaq.com/market-activity/stocks/illr/press-releases $META $NXL

0 · Reply

Dante_s_Inferno Nov. 18 at 3:14 PM

$NXL f* scam

0 · Reply

MrTicker Nov. 18 at 2:03 PM

$NXL Nexalin Technology Study On 15 Milliamp Neurostimulation Device Demonstrates Safety, Efficacy In Participant With Gambling Disorder, Alcohol Use Disorder BENZINGA 8:03 AM ET 11/18/2025

0 · Reply

MrTicker Nov. 18 at 2:01 PM

$NXL Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use ComorbidityPeer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapy GLOBENEWSWIRE 8:00 AM ET 11/18/2025

0 · Reply

Stock_Catcher Nov. 18 at 2:00 PM

$NXL Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

0 · Reply

d_risk Nov. 14 at 3:39 PM

$NXL - Nexalin Technology, Inc. - 10Q - Updated Risk Factors NXL flags heightened uncertainty from new U.S. tariff hikes and global retaliatory trade restrictions, warning of possible hits to sales and operations. #TechnologySector #GlobalUncertainty #SalesRisk #TariffImpact #TradeRestrictions 🟢 Added 🟠 Removed https://d-risk.ai/NXL/10-Q/2025-11-14

0 · Reply

MrTicker Nov. 13 at 7:14 PM

$NXL didn't run all day on news.. could see some action during power hr or after hours.

0 · Reply

MrTicker Nov. 13 at 7:13 PM

$NXL 02:11 PM EST, 11/13/2025 (MT Newswires) -- Nexalin Technology(NXL) said Thursday it entered into a distribution agreement with Israeli medical device distributor Carmi Masha Technologies to market and sell its Gen-2 Console non-invasive neurostimulation device throughout Israel. The agreement follows regulatory approval by the Israeli Ministry of Health, authorizing the commercial sale of the device for the treatment of mental health disorders, including insomnia, depression, and anxiety.

0 · Reply

MrTicker Nov. 13 at 7:13 PM

$NXL Nexalin Technology Enters Distribution Deal in Israel for Neurostimulation Device MT NEWSWIRES 1:11 PM ET 11/13/2025

0 · Reply

Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

Nov 13, 2025, 9:15 AM EST - 12 days ago

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

Nov 5, 2025, 8:30 AM EST - 20 days ago

Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia

Oct 30, 2025, 8:30 AM EDT - 26 days ago

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

Oct 21, 2025, 9:00 AM EDT - 5 weeks ago

Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies

Oct 13, 2025, 8:30 AM EDT - 6 weeks ago

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs

Oct 10, 2025, 8:00 AM EDT - 6 weeks ago

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

Oct 8, 2025, 2:45 PM EDT - 6 weeks ago

Why Is Micro-Cap Stock Nexalin Technology Rallying On Wednesday?

Oct 8, 2025, 8:30 AM EDT - 6 weeks ago

Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer's Disease with Gen-2 SYNC Neurostimulation Device

Sep 25, 2025, 8:30 AM EDT - 2 months ago

Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology

Aug 25, 2025, 9:00 AM EDT - 3 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on September 9

Aug 1, 2025, 8:30 AM EDT - 4 months ago

Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin's Next Phase of Growth and Strategic Initiatives

May 28, 2025, 10:00 AM EDT - 6 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on June 3

May 13, 2025, 8:30 AM EDT - 7 months ago

Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging Data

May 6, 2025, 2:40 PM EDT - 7 months ago

Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering

May 5, 2025, 8:20 AM EDT - 7 months ago

Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock

May 1, 2025, 10:30 AM EDT - 7 months ago

Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback

Apr 24, 2025, 9:00 AM EDT - 7 months ago

Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia

Apr 23, 2025, 9:15 AM EDT - 7 months ago

Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management

Apr 21, 2025, 8:00 AM EDT - 7 months ago

Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices

Apr 14, 2025, 12:30 PM EDT - 8 months ago

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Apr 2, 2025, 8:30 AM EDT - 8 months ago

Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial

Mar 26, 2025, 8:30 AM EDT - 8 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on April 3

Mar 3, 2025, 8:30 AM EST - 9 months ago

Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders

Feb 28, 2025, 8:30 AM EST - 9 months ago

Nexalin Technology Announces Initiation of Patient Recruitment for UCSD's TBI & PTSD Clinical Study Following IRB Approval

Feb 26, 2025, 8:30 AM EST - 9 months ago

Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

Feb 18, 2025, 8:30 AM EST - 10 months ago

Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment

Feb 10, 2025, 9:00 AM EST - 10 months ago

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

Feb 3, 2025, 8:30 AM EST - 10 months ago

Nexalin's Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

Jan 23, 2025, 11:00 AM EST - 10 months ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session, Today, January 23

Dec 23, 2024, 10:00 AM EST - 1 year ago

Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic

Nov 26, 2024, 10:00 AM EST - 1 year ago

New Peer-Reviewed Publication Validates Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market

Nov 1, 2024, 2:00 PM EDT - 1 year ago

Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on November 5th

Nov 1, 2024, 10:34 AM EDT - 1 year ago

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

Nov 1, 2024, 9:00 AM EDT - 1 year ago

LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Oct 25, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

CLDI

Oct 22, 2024, 2:15 PM EDT - 1 year ago

Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA

Oct 17, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Nexalin's Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer's Patients

Oct 14, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs

Sep 5, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment

Jul 26, 2024, 9:55 AM EDT - 1 year ago

Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

LOBO

Jul 18, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery

Jul 1, 2024, 2:45 PM EDT - 1 year ago

Nexalin Technology Announces Closing of $5.2 Million Public Offering

Jun 27, 2024, 9:15 PM EDT - 1 year ago

Nexalin Technology Announces Pricing of $5.2 Million Public Offering

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer's and Dementia

Jun 14, 2024, 9:00 AM EDT - 1 year ago

Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

VNRX

Jun 13, 2024, 3:00 PM EDT - 1 year ago

Nexalin Technology Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th

Jun 3, 2024, 8:30 AM EDT - 1 year ago

FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device

Azlvr Nov. 21 at 7:42 PM

$NXL 😬 https://www.trustpilot.com/review/www.jccapitalconsultants.com

0 · Reply

Stockprofiler Nov. 18 at 5:43 PM

0 · Reply

Dante_s_Inferno Nov. 18 at 3:14 PM

$NXL f* scam

0 · Reply

MrTicker Nov. 18 at 2:03 PM

$NXL Nexalin Technology Study On 15 Milliamp Neurostimulation Device Demonstrates Safety, Efficacy In Participant With Gambling Disorder, Alcohol Use Disorder BENZINGA 8:03 AM ET 11/18/2025

0 · Reply

MrTicker Nov. 18 at 2:01 PM

0 · Reply

Stock_Catcher Nov. 18 at 2:00 PM

$NXL Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

0 · Reply

d_risk Nov. 14 at 3:39 PM

0 · Reply

MrTicker Nov. 13 at 7:14 PM

$NXL didn't run all day on news.. could see some action during power hr or after hours.

0 · Reply

MrTicker Nov. 13 at 7:13 PM

0 · Reply

MrTicker Nov. 13 at 7:13 PM

$NXL Nexalin Technology Enters Distribution Deal in Israel for Neurostimulation Device MT NEWSWIRES 1:11 PM ET 11/13/2025

0 · Reply

Dante_s_Inferno Nov. 13 at 6:26 PM

$NXL news and…down 👍🏻

0 · Reply

MrTicker Nov. 13 at 2:23 PM

$NXL Nexalin Technology Signs Exclusive Distribution Agreement With Carmi Masha Technologies To Advertise, Sell Nexalin's Gen-2 Console In Israel BENZINGA 8:21 AM ET 11/13/2025

0 · Reply

MrTicker Nov. 13 at 2:16 PM

$NXL Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in IsraelAppointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC Device GLOBENEWSWIRE 8:15 AM ET 11/13/2025

0 · Reply

BATMAN666 Nov. 6 at 2:38 PM

$NXL Why this under 2$ so far!!

0 · Reply

Dante_s_Inferno Nov. 6 at 1:35 PM

$NXL 3k already red again 🙈 pos

0 · Reply

MasterOfMyDomains Nov. 6 at 12:55 PM

$NXL

0 · Reply

Option_trader11 Nov. 5 at 4:55 PM

$NXL this should be 2 plus

0 · Reply

JL_TradeZ Nov. 5 at 2:26 PM

Solid premarket so far $SMX +51%, $NVVE +31%, $NXL +15%, $ZDAI small red. NXL still open and holding small for market opens. Nice early momentum heading into the open 🔥

1 · Reply

OpenOutcrier Nov. 5 at 2:08 PM

$NXL (+3.6% pre) FDA accepts Nexalin Q-submission for Alzheimer's treatment device https://ooc.bz/l/83286

0 · Reply

treblclef20 Nov. 5 at 2:04 PM

$NXL don't get it. this is actually decent news. looking for volume....

1 · Reply

Laurapicksright Nov. 5 at 1:44 PM

$PRFX massive volume building for the squeeze this is massive $NVDA news 😍😍 Watching $SMX $CHR.X $NXL

0 · Reply

treblclef20 Nov. 5 at 1:44 PM

$NXL where is the volume ?

0 · Reply

Market Cap	18.84M
Revenue (ttm)	170,000.00
Net Income (ttm)	-7.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,476.47%
Debt to Equity Ratio	0.00

Volume	86,300
Avg Vol	4,449,846
Day's Range	N/A - N/A
Shares Out	18.65M
Stochastic %K	35%
Beta	3.63
Analysts	Strong Sell
Price Target	$4.00